Stock of the Day: West Pharmaceutical Services Inc (NYSE:WST) Institutional Investors Sentiment Unchanged in Q2 2016

December 1, 2016 - By Ellis Scott   ·   0 Comments

Stock of the Day: West Pharmaceutical Services Inc (NYSE:WST) Institutional Investors Sentiment Unchanged in  Q2 2016

Sentiment for West Pharmaceutical Services Inc (NYSE:WST)

West Pharmaceutical Services Inc (NYSE:WST) institutional sentiment decreased to 1.01 in Q2 2016. Its down -0.10, from 1.11 in 2016Q1. The ratio dived, as 130 funds opened new and increased stock positions, while 117 sold and decreased their stock positions in West Pharmaceutical Services Inc. The funds in our partner’s database now have: 65.20 million shares, down from 67.68 million shares in 2016Q1. Also, the number of funds holding West Pharmaceutical Services Inc in their top 10 stock positions increased from 5 to 6 for an increase of 1. Sold All: 15 Reduced: 102 Increased: 79 New Position: 51.

West Pharmaceutical Services, Inc. is a maker of components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. The company has a market cap of $5.78 billion. The Company’s divisions include Pharmaceutical Packaging Systems segment (Packaging Systems) and the Pharmaceutical Delivery Systems segment (Delivery Systems). It has a 43.38 P/E ratio. The Company’s Packaging Systems segment includes primary packaging components and systems for injectable drug delivery, other components used in syringe, intravenous and blood collection systems, and prefillable syringe components.

About 130,898 shares traded hands. West Pharmaceutical Services Inc. (NYSE:WST) has risen 12.29% since April 28, 2016 and is uptrending. It has outperformed by 6.36% the S&P500.

Analysts await West Pharmaceutical Services Inc. (NYSE:WST) to report earnings on February, 16. They expect $0.55 earnings per share, up 17.02% or $0.08 from last year’s $0.47 per share. WST’s profit will be $39.64 million for 36.45 P/E if the $0.55 EPS becomes a reality. After $0.53 actual earnings per share reported by West Pharmaceutical Services Inc. for the previous quarter, Wall Street now forecasts 3.77% EPS growth.

According to Zacks Investment Research, “West Pharmaceutical Services applies technologies to the process of bringing new drug therapies and healthcare products. West’s technologies include the design and manufacture of packaging components for pharmaceutical, healthcare and consumer products; research and development of drug delivery systems; contract manufacturing and packaging services; clinical services; and contract laboratory services and other services that support the manufacturing, filling and packaging of pharmaceutical, healthcare and consumer products.”

Kistler holds 2.83% of its portfolio in West Pharmaceutical Services Inc. for 72,724 shares. Kalmar Investments Inc De owns 830,860 shares or 2.78% of their US portfolio. Moreover, Irving Magee Investment Management has 2.6% invested in the company for 70,142 shares. The Massachusetts-based Copper Rock Capital Partners Llc has invested 1.98% in the stock. Hermes Investment Management Ltd, a United Kingdom-based fund reported 1.08 million shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 0 insider buys, and 3 insider sales for $1.65 million net activity.

West Pharmaceutical Services Inc. (NYSE:WST) Ratings Coverage

Ratings analysis reveals 100% of West Pharmaceutical Services’s analysts are positive. Out of 2 Wall Street analysts rating West Pharmaceutical Services, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. WST was included in 5 notes of analysts from August 4, 2015. The rating was initiated by Wells Fargo on Tuesday, March 22 with “Outperform”. Janney Capital initiated the shares of WST in a report on Friday, January 8 with “Buy” rating. On Tuesday, August 4 the stock rating was downgraded by Zacks to “Hold”. The rating was upgraded by Wells Fargo on Friday, October 28 to “Outperform”. The firm has “Market Perform” rating by Wells Fargo given on Wednesday, September 21.

WST Company Profile

West Pharmaceutical Services, Inc. (West), incorporated on July 27, 1923, is a maker of components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. The Company’s divisions include Pharmaceutical Packaging Systems segment (Packaging Systems) and the Pharmaceutical Delivery Systems segment (Delivery Systems). The Company’s products include stoppers and seals for vials, and contract design and manufacturing services. The Company’s clients include producers of pharmaceuticals, biologics, medical devices and consumer products.

More notable recent West Pharmaceutical Services Inc. (NYSE:WST) news were published by: Prnewswire.com which released: “West Announces Expanded Contract Manufacturing Capabilities in Ireland” on November 29, 2016, also Prnewswire.com with their article: “West Appoints David A. Montecalvo Senior Vice President, Global Operations and …” published on September 26, 2016, Prnewswire.com published: “West Elects New Director and Announces Increase to Quarterly Dividend” on September 12, 2016. More interesting news about West Pharmaceutical Services Inc. (NYSE:WST) were released by: Equitiesfocus.com and their article: “West Pharmaceutical Services, Inc. (NYSE:WST) Posted Basic Consolidated EPS Of …” published on December 01, 2016 as well as Nasdaq.com‘s news article titled: “West Pharmaceutical Services, Inc. (WST) Ex-Dividend Date Scheduled for …” with publication date: October 14, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ellis Scott


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>